Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours

British Journal of Cancer

Volumn 109, Issue 1, 2013, Pages 68-75

  Mendoza, J ^a   Martinez J ^b   Hernandez C ^c   Perez Montiel D ^b   Castro, C ^a   Fabian Morales E ^a   Santibanez M ^a   Gonzalez Barrios R ^a   Diaz Chavez J ^a   Andonegui, M A ^a   Reynoso, N ^a   Onate L F ^a   Jimenez M A ^b   Nunez M ^d   Dyer, R ^d   Herrera, L A ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c Hospital Regional Presidente Juárez ISSSTE   (Mexico)

^d INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GAMMA H2AX PROTEIN; HISTONE H2AX; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

5' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; GENE FREQUENCY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; HISTONES; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL RATE; TESTICULAR NEOPLASMS; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 84880262399     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.303     Document Type: Article

References (30)

1. Al-Haddad S, Zhang Z, Leygue E, Snell L, Huang A, Niu Y, Hiller-Hitchcock T, Hole K, Murphy LC, Watson PH (1999) Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 155(6): 2057-2066.
2. Fenske AE, Glaesener S, Bokemeyer C, Thomale J, Dahm-Daphi J, Honecker F, Dartsch DC (2012) Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair. Cancer Lett 324(2): 171-178.
3. Globocan (2008) Testis cancer incidence and mortality worldwide in 2008 http://globocan.iarc.fr.
4. Handra-Luca A, Bilal H, Bertrand JC, Fouret P (2003) Extra-cellular signalregulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol 163(3): 957-967.
5. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P (2007) Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13(13): 3855-3859.
6. Honecker F (2003) Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors. Lab Invest 83: 1489-1495.
7. Horwich A, Shipley J, Huddart R (2006) Testicular germ-cell cancer. Lancet 367: 754-765.
8. Jones RH, Vasey PA (2003) Part II: testicular cancer-management of advanced disease. Lancet Oncol 4(12) 738-747.
9. Köberle B, Brenner W, Albers A, Usanova S, Thuroff JW, Kaina B (2010) ERCC1 and XPF expression in human testicular germ cell tumors. Oncol Rep 23(1): 223-227.
10. Köberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR (1997) DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 70(5): 551-555.
11. Köberle B, Masters JR, Ja Hartley, Wood RD (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9: 273-276.
12. Köberle B, Payne J, Ka Grimaldi, Ja Hartley, Masters JR (1996) DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol 52: 1729-1734.
13. Köberle B, Roginskaya V, Zima KS, Masters JRW, Wood RD (2008) Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation. Mol Carcinog 47: 580-586.
14. Leibeling D, Laspe P, Emmert S (2006) Nucleotide excision repair and cancer. J Mol Histol 37(5-7): 225-238.
15. Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LHJ, Bokemeyer C (2003) Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9: 767-773.
16. Olaussen Ka, Fouret P, Kroemer G (2007) ERCC1-specific immunostaining in non-small-cell lung cancer. N Engl J Med 357: 1559-1561.
17. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ (2003) ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1(3): 162-166.
18. Park J-S, Jeon EK, Chun SH, Won HS, Lee A, Hur SY, Lee KH, Bae S-N, Yoon S-C, Hong SH (2011) ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer. Gynecol Oncol 120: 275-279.
19. Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos A-T, Follen M, Wu X (2007) Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 107: S223-S229.
20. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, HoeltlW, Joffe J, JonesW, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15(9): 1377-1399.
21. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.
22. Steffensen KD, Waldstrom M, Jeppesen U, Brandslund I, Jakobsen A (2008) Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer 18(4): 702-710.
23. Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B (2005) Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer 103: 2313-2319.
24. Taverna P, Hansson J, Scanlon KJ, Hill BT (1994) Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis 15(9): 2053-2056.
25. Usanova S, Piée-Staffa A, Sied U, Thomale J, Schneider A, Kaina B, Köberle B (2010) Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 9: 248.
26. Welsh C, Day R, McGurk C, Masters JRW, Wood RD, Köberle B (2004) Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 110: 352-361.
27. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316(23): 1435-1440.
28. Wood RD, Mitchell M, Lindahl T (2005) Human DNA repair genes, 2005. Mutat Res 577: 275-283.
29. Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, Mitchell KC, Reed E (1997) A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 382(1-2): 13-20.
30. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10: 4939-4943.